Evidence-Based Guide

Hyperhidrosis

A physician's evidence-based guide to primary hyperhidrosis, stepwise treatment (aluminum chloride to Qbrexza to Botox), oxybutynin, iontophoresis, miraDry, and what actually works in 2026.

What is the best treatment for hyperhidrosis (excessive sweating) in 2026?

Hyperhidrosis affects an estimated 4.8% of the U.S. population (about 15.3 million people), yet only 51% of those affected had discussed it with a healthcare professional (Doolittle et al., Arch Dermatol Res 2016). The Canadian Hyperhidrosis Advisory Committee severity-based algorithm starts mild (HDSS score 2) axillary, palmar, or plantar disease on topical aluminum chloride, with botulinum toxin A (axillae, palms, soles) and iontophoresis (palms, soles) as second-line therapy if that fails; in severe disease (HDSS score 3 or 4), botulinum toxin A and topical aluminum chloride are both first-line. Topical glycopyrronium (Qbrexza) and sofpironium gel (Sofdra) are FDA-approved for primary axillary hyperhidrosis in patients 9 years of age and older (Qbrexza label; Sofdra label). Oral anticholinergics such as oxybutynin are off-label options reserved for treatment-resistant or generalized sweating (Nawrocki and Cha, J Am Acad Dermatol 2019). miraDry (microwave thermolysis) is FDA-cleared for the underarms, and endoscopic thoracic sympathectomy is the treatment of last resort because of compensatory sweating. Every serious attempt at treating excessive sweating starts with confirming primary versus secondary hyperhidrosis. A licensed clinician, accessible via telehealth, can start most first-line and second-line therapies without an in-person visit.
Medically reviewed by Parth Bhavsar, MD. Updated July 18, 2026.

Key Takeaways

  • Hyperhidrosis affects an estimated 4.8% of the U.S. population (about 15.3 million people), yet only 51% of those affected had discussed it with a healthcare professional, most often because they did not see it as a medical condition or believed nothing could be done.[1]
  • Primary vs secondary distinction is step one. Primary hyperhidrosis is symmetrical and focal (axillae, palms, soles, face), typically starts before age 25, often runs in families, and stops during sleep.[9][12] Secondary hyperhidrosis is caused by a medication or another medical condition, usually affects most of the body, can cause sweating during sleep, and needs to be excluded before diagnosing primary disease.[12][17][18]
  • The Hyperhidrosis Disease Severity Scale (HDSS) is the standard tool for tailoring treatment. In the Canadian severity-based algorithm, a score of 3 or 4 (severe) makes botulinum toxin A and topical aluminum chloride both first-line options, rather than reserving botulinum toxin for topical failure.[3]
  • Topical aluminum chloride is first-line for mild axillary, palmar, and plantar disease.[3] It is applied to dry skin at bedtime and left to dry completely; once sweating is under control, usually within a few weeks, most people use it once or twice a week.[2]
  • Qbrexza (glycopyrronium 2.4% cloth) was FDA-approved in 2018 for primary axillary hyperhidrosis in ages 9 and older.[7] In the pivotal ATMOS-1 and ATMOS-2 trials (697 subjects), significantly more Qbrexza than vehicle patients achieved a 4-point or greater improvement in sweat severity score at week 4 (59.5% vs 27.6%).[4][7]
  • Botulinum toxin A (Botox) is FDA-approved for severe underarm sweating in adults that topical agents have not controlled.[15] In the pivotal Naumann and Lowe 2001 trial (320 patients randomized), 82% of botulinum toxin patients versus 21% on placebo still had a 50% or greater reduction in sweat production at week 16.[5] In a 52-week trial, the median duration of effect was 197 to 205 days.[6]
  • Many first steps can start by telehealth. Aluminum chloride, Qbrexza, oxybutynin, glycopyrrolate, and iontophoresis referrals can all be initiated from a synchronous telehealth visit.
Editorial medical illustration representing Hyperhidrosis
Hyperhidrosis: an evidence-based overview from Parth Bhavsar, MD.

Hyperhidrosis, excessive sweating beyond what is needed for thermoregulation, affects millions of Americans, yet remains under-recognized and under-treated. This guide is a physician's evidence-based look at how hyperhidrosis is diagnosed, how the stepwise treatment ladder from aluminum chloride to Qbrexza to botulinum toxin actually works, and what the evidence says about iontophoresis, oral anticholinergics, and permanent options like miraDry and endoscopic thoracic sympathectomy in 2026. Material claims are cited to the numbered sources listed at the end.

What Is Hyperhidrosis?

Hyperhidrosis is a condition of sweating in excess of what is needed to regulate normal body temperature. It is classified as either primary (idiopathic, focal) or secondary (caused by an underlying medical condition or medication).[1] The distinction is not academic. It determines whether a patient needs a diagnostic workup or can move directly to symptom-based treatment.

Primary vs secondary hyperhidrosis

Primary focal hyperhidrosis is the more common presentation: about 93% of patients with hyperhidrosis have primary disease, and more than 90% of them have a focal, bilateral distribution affecting the axillae, palms, soles, or craniofacial areas.[12] It typically begins before age 25 and, critically, stops during sleep; a family predisposition is common, supporting a genetic basis.[9] Secondary hyperhidrosis, by contrast, usually causes heavy sweating over most of the body, can cause sweating during sleep, and is driven by an identifiable cause such as an endocrine disorder, a medication, a tumor, or a disorder of the nervous system.[9][17][18]

Focal patterns: axillary, palmar, plantar, craniofacial

Primary focal hyperhidrosis has four characteristic distributions, and many patients have more than one simultaneously:

  • Axillary (underarm): the most common presentation for which patients seek treatment, and the pattern with the most FDA-approved options, including Qbrexza and botulinum toxin A
  • Palmar (palms): often the most socially and occupationally disruptive, given its impact on handshakes, paperwork, touchscreens, and grip
  • Plantar (soles): frequently coexists with palmar disease, contributes to skin maceration and secondary infection risk
  • Craniofacial (face and scalp): disproportionately distressing due to visibility, harder to treat topically

In a 2016 nationally representative U.S. survey, the underarms were the most commonly reported area: 65% of respondents had axillary sweating, alone or with other areas. The head or face was the area most often reported together with the underarms, by 29% of respondents.[1]

HDSS: measuring severity

The Hyperhidrosis Disease Severity Scale (HDSS) is a four-point, single-item scale that rates sweating by how tolerable it is and how much it interferes with daily activities.[1] A score of 3 or 4 (sweating is barely tolerable or intolerable and frequently or always interferes with daily activities) is considered severe.[1] In the Canadian algorithm, severity changes the starting point rather than only the escalation step: for a score of 3 or 4, botulinum toxin A and topical aluminum chloride are both first-line therapy.[3] Trials also use the HDSS to track response; in a 52-week trial, a 2-point improvement was reported in 75% of patients given botulinum toxin and 25% given placebo.[6]

Primary vs secondary is step one

Before starting any hyperhidrosis treatment, confirm the pattern is consistent with primary disease: focal, symmetric, onset before age 25, and stops during sleep. Sweating that is generalized, asymmetric, or continues overnight warrants a workup for secondary causes before symptomatic treatment begins.

What Causes Hyperhidrosis?

Primary hyperhidrosis: autonomic dysregulation

Primary focal hyperhidrosis is thought to result from a localized abnormality in the sympathetic nervous system's control of eccrine sweat glands rather than the glands themselves being structurally abnormal. The eccrine glands are histologically normal in number and structure. The dysfunction lies in the central and peripheral neural signaling that triggers sweat gland activation, meaning the glands are essentially normal, but the "on switch" is set too sensitively, firing in response to emotional and other non-thermal triggers, not just heat.[12] This autonomic dysregulation explains why primary hyperhidrosis responds well to treatments that block the neural or receptor-level signal (anticholinergics, botulinum toxin) rather than treatments that would address a structural gland problem.

Secondary causes to rule out

Secondary hyperhidrosis has a broad differential, spanning endocrine disorders, drugs, tumors, and abnormalities of the nervous system.[9] Medical conditions named by the AAD include diabetes, Parkinson's disease, rheumatoid arthritis, heart failure, stroke, and menopause, and medications include some antibiotics, antivirals, insulin, and antidepressants.[17] Clinically relevant categories include:

  • Endocrine: hyperthyroidism, diabetes mellitus (including hypoglycemia), menopause, pheochromocytoma, carcinoid syndrome, acromegaly
  • Neurologic: Parkinson's disease, stroke, spinal cord injury, peripheral neuropathy
  • Infectious: tuberculosis, HIV, endocarditis
  • Malignancy: lymphoma and other cancers associated with paraneoplastic sweating and night sweats
  • Medications: SSRIs and SNRIs, tricyclic antidepressants, opioids, antipsychotics, certain diabetes medications
  • Other: anxiety disorders, obesity, pregnancy

A history and physical exam that supports the primary pattern (focal, symmetric, sleep-sparing, early onset, family history) generally obviates the need for extensive secondary workup. When features are atypical, generalized sweating, night sweats, adult onset without family history, or accompanying weight loss, palpitations, or fever, a basic panel (TSH, fasting glucose or HbA1c, chest X-ray, and a careful medication review) is a reasonable starting point.

What's Changed in 2024 to 2026

Hyperhidrosis treatment has seen incremental but meaningful movement over the past two to three years, spanning new drug approvals, expanded indications, and improved access.

Qbrexza's label now stresses accidental exposure. Qbrexza (a cloth pre-moistened with 2.4% glycopyrronium solution) has been approved since 2018 for primary axillary hyperhidrosis in patients 9 years of age and older. Its label reports postmarketing cases of accidental exposure causing dilated pupils, unequal pupils, and blurred vision, including children who got into discarded wipes, so hand washing and careful disposal matter.[7]

Sofdra (sofpironium bromide) reached the US market. Sofdra, a topical anticholinergic gel, received FDA approval in 2024 for primary axillary hyperhidrosis in adults and children 9 years of age and older, and is a second topical anticholinergic option alongside Qbrexza.[13]

Oral oxybutynin evidence is supportive but still limited. A randomized placebo-controlled trial supports low-dose oral oxybutynin as an initial option for palmar and axillary hyperhidrosis,[8] and a 2017 review described recent longer follow-up studies as encouraging while noting that longer studies are still needed to establish the drug's safety and long-term results.[9]

MiraDry remains an underarm-only device option. Microwave thermolysis devices such as miraDry are FDA-cleared for primary axillary hyperhidrosis,[14] and the AAD describes the treatment as long-lasting but expensive and not covered by most health insurance plans.[2]

Telehealth can lower the barrier to a first visit. Aluminum chloride, Qbrexza, Sofdra, oral oxybutynin, and glycopyrrolate can all be initiated through a synchronous telehealth visit, expanding access for patients who might otherwise avoid seeking care. This matters clinically because many people with hyperhidrosis never raise it: in a 2016 survey, only 51% of those affected had discussed it with a healthcare professional.[1] A lower-friction path to a prescription can help close that gap.

Taken together, these shifts have not changed the fundamental treatment ladder, aluminum chloride still comes first, botulinum toxin is still the standard second-line procedural option, but they have added more topical options between first-line antiperspirants and injectable therapy, and they have made the entire pathway easier to access without an in-person dermatology referral for the first several steps.

Decision Framework: How Sweating Severity and Location Drive Treatment

Choosing a hyperhidrosis treatment depends on two variables above all others: which body region is affected and how severe the sweating is on the HDSS. The table below is adapted from the Canadian Hyperhidrosis Advisory Committee's severity- and location-based algorithm,[3] with the newer topical anticholinergics added; it is this guide's summary, not a reproduction of that algorithm.

HDSS ScoreLocationFirst-lineSecond-lineThird-linePermanent option
2 (mild-mod) Axilla Aluminum chloride 20% Qbrexza; Botox Oral anticholinergic miraDry
2 (mild-mod) Palm/sole Aluminum chloride 20% Iontophoresis; Botox Oral anticholinergic ETS (palmar only)
2 (mild-mod) Face Aluminum chloride (limited) Oral anticholinergic Botox (none)
3-4 (severe) Axilla Aluminum chloride + Qbrexza or Botox Add oral anticholinergic miraDry ETS (rare)
3-4 (severe) Palm/sole Iontophoresis + Botox Add oral anticholinergic ETS (palmar) ETS
3-4 (severe) Face Oral anticholinergic Botox (limited) (limited)
Generalized Whole body Oral oxybutynin or glycopyrrolate Combination therapy Refer to dermatology (none)

This framework is a starting point, not a rigid protocol. In practice, most patients move through it iteratively: a topical agent is often tried first because it is low-risk and inexpensive, although for severe disease the Canadian algorithm lists botulinum toxin A as an equal first-line option.[3] The HDSS score is reassessed at each follow-up, and escalation happens only when a treatment tried at an adequate dose and duration fails to bring the score down to a tolerable level (typically 1 or 2). Combination therapy, for example aluminum chloride plus Qbrexza, or iontophoresis plus a low-dose oral anticholinergic, is common in clinical practice, although a 2020 systematic review concluded that the current evidence does not allow statements about the comparative effectiveness of hyperhidrosis treatments.[14]

First-Line Therapy: Topical Antiperspirants

Aluminum chloride 20%: the workhorse

Topical aluminum chloride remains the first-line treatment for mild axillary, palmar, and plantar hyperhidrosis,[3] and prescription-strength aluminum chloride antiperspirants are the recommended first-line option for most cases of hyperhidrosis.[1] Aluminum salts are thought to work by damaging the cells lining the sweat duct, creating a plug that obstructs the sweat glands.[14] They can be moderately effective in the short term, but results are less satisfactory in the long run and skin irritation at the application site is a common problem.[1]

Application technique

Technique matters for aluminum chloride's efficacy and tolerability. It should be applied to dry skin at bedtime and allowed to dry completely before going to bed. It is used nightly until the excessive sweating is under control, which usually happens within a few weeks, and then as needed, usually once or twice a week. If the skin becomes irritated, increasing the time between applications is one of the fixes the AAD suggests.[2]

When to escalate

Escalation to second-line therapy is appropriate when aluminum chloride, used correctly and consistently for a few weeks, fails to produce meaningful HDSS improvement, or when irritation (contact dermatitis, burning, itching) prevents continued use. Given how commonly technique errors (damp skin, daytime application) explain apparent treatment failure, confirming correct application before concluding a patient has failed first-line therapy is a worthwhile step.

Topical Anticholinergics: Qbrexza and Sofdra

Qbrexza (glycopyrronium 2.4% cloth)

Qbrexza is a single-use cloth pre-moistened with 2.4% glycopyrronium solution, FDA-approved in 2018 for primary axillary hyperhidrosis in patients 9 years of age and older. One cloth is used once daily for both underarms, no more often than once every 24 hours. It is a competitive inhibitor of acetylcholine receptors on peripheral tissues, including sweat glands.[7] In the pivotal ATMOS-1 and ATMOS-2 phase 3 trials (697 subjects in total), significantly more Qbrexza-treated patients than vehicle-treated patients achieved a 4-point or greater improvement on the Axillary Sweating Daily Diary Item 2 score at week 4 (59.5% vs 27.6% in pooled data), with a significant reduction in gravimetrically measured sweat production.[4][7]

Sofdra (sofpironium)

Sofdra (sofpironium 12.45% gel, equivalent to 15% sofpironium bromide) is a newer topical anticholinergic, FDA-approved in 2024 for primary axillary hyperhidrosis in adults and children 9 years of age and older. One pump is applied to each clean, dry underarm once a day at bedtime, without showering for at least 30 minutes before or 8 hours after application.[13] In practice, the choice between Sofdra and Qbrexza is often guided by insurance formulary coverage and individual tolerability.

Anticholinergic side effects

Both Qbrexza and Sofdra carry class-wide anticholinergic side effects. In the trials summarized in their labels, dry mouth was the most common (24.2% with Qbrexza and 14% with Sofdra), and dilated pupils (mydriasis) and blurred vision also occurred; Sofdra also commonly caused application-site pain, redness, and dermatitis.[7][13] Both labels warn about new or worsening urinary retention, heat illness from reduced sweating, and transient blurred vision when driving or operating machinery, and both are contraindicated in conditions that anticholinergic effects can worsen, such as glaucoma.[7][13] Patients should wash their hands immediately after application and avoid transfer to the area around the eyes.[7][13]

HDSS: how to measure severity

The Hyperhidrosis Disease Severity Scale is a single question: how would you rate the tolerability of your sweating? A score of 3 or 4 means sweating is barely tolerable or intolerable and frequently or always interferes with daily activities. In the Canadian algorithm, that severity makes botulinum toxin A and topical aluminum chloride both first-line, and iontophoresis is also first-line for palms and soles.[3]

Iontophoresis: For Palms and Soles

Evidence and efficacy

Iontophoresis involves placing the hands or feet in a pan of tap water while a direct electric current goes into the water and enters the surface of the skin.[2] The mechanism is not known; hypotheses include inhibition of nerve transmission and obstruction of sweat flow through changes in pH or ion deposition in the sweat ducts.[14] It is considered the primary remedy for palmar and plantar hyperhidrosis,[10] and the FDA has cleared iontophoresis machines to treat hyperhidrosis on the hands and feet.[2] The studies behind it are small: a 2020 systematic review found large response rates but rated the evidence as insufficient to compare iontophoresis with other therapies for palmar hyperhidrosis.[14]

Home devices vs clinic sessions

Iontophoresis can be delivered in a clinic or with a machine bought for home use.[2] Home treatment avoids recurring visits, while clinic-based treatment avoids buying a device. For most patients pursuing iontophoresis long-term, a home device is more convenient.

Practical protocol

At the start, patients usually treat for 20 to 30 minutes, daily or once every 2 to 5 days, and results usually appear after 5 to 10 treatments. After that, most patients can maintain their results by treating once a week or every other week.[2] Follow the device instructions on current settings and skin care during sessions.

Oral Anticholinergics: Oxybutynin and Glycopyrrolate

When to use

Oral systemic agents are reserved for treatment-resistant cases or for generalized hyperhidrosis,[10] and are sometimes used as an adjunct alongside topical or procedural treatment for partial responders. Neither oral oxybutynin nor oral glycopyrrolate is FDA-approved for hyperhidrosis; oxybutynin tablets, for example, are labeled for bladder symptoms,[16] so both are used off-label for sweating.[14] Unlike topical agents, oral anticholinergics act systemically, reducing sweat production across all eccrine glands rather than only in the treated area.

Dosing and titration

Oral oxybutynin is started low and titrated. In a randomized, placebo-controlled trial in 50 patients with palmar hyperhidrosis, patients took 2.5 mg once daily in the evening for the first week, 2.5 mg twice daily from days 8 to 21, and 5 mg twice daily from day 22 to the end of week 6. Palmar and axillary hyperhidrosis improved in more than 70% of patients, and dry mouth was the most frequent side effect (47.8%).[8] A 2017 narrative review concluded that oxybutynin is an efficient option with a low level of adverse events, while noting that studies with longer follow-up are needed to establish long-term safety and results.[9] Oral glycopyrrolate is another off-label oral anticholinergic that the AAD groups with oxybutynin, with the same kinds of side effects;[2] its dose for sweating is set and adjusted by the prescriber.

Anticholinergic burden considerations

Systemic anticholinergic side effects are the main limiting factor for oral therapy. The AAD lists dry mouth (most common), constipation, drowsiness, and dilated pupils, and advises avoiding hot temperatures, because reduced sweating makes it harder to cool down and fever or heat stroke can occur.[2] The oxybutynin label warns about heat prostration due to decreased sweating and anticholinergic central nervous system effects such as drowsiness and blurred vision, advises cautious dose selection in older adults, and lists urinary retention, gastric retention, and uncontrolled narrow-angle glaucoma as contraindications.[16] Older patients and those on other anticholinergic medications (some antihistamines, tricyclic antidepressants, bladder antimuscarinics) add to their overall anticholinergic burden. Starting at a low dose and titrating slowly, and periodically reassessing whether the current dose remains necessary, is the standard mitigation strategy.

Botulinum Toxin A: The Second-Line Standard

Axillary Botox

Botulinum toxin A blocks the autonomic cholinergic fibers, including the sympathetic fibers to sweat glands, producing localized loss of sweating.[11] Its potential for hyperhidrosis was shown in a mid-1990s study in healthy volunteers, in whom 50 units injected into the underarm abolished axillary sweating; the authors proposed it as a possible treatment for severe axillary hyperhidrosis.[11] Botox is FDA-approved for severe axillary hyperhidrosis that is inadequately managed with topical agents in adult patients, at a recommended dose of 50 units per axilla.[15] The pivotal Naumann and Lowe 2001 randomized, placebo-controlled trial (320 patients randomized) defined response as a 50 percent or greater reduction in sweat production: 94 percent of botulinum toxin patients versus 36 percent of placebo patients responded at week 4, and 82 percent versus 21 percent at week 16.[5] A subsequent 52-week multicenter trial of 322 patients found that botulinum toxin effectively reduced symptoms and was well tolerated.[6] The Botox label carries a boxed warning that the effects of botulinum toxin products may spread beyond the injection site, and lists injection site pain and bleeding, sweating outside the underarms, sore throat, and flu-like symptoms as the most common side effects in axillary hyperhidrosis.[15]

Palmar and plantar Botox

Dermatologists also use botulinum toxin for excessive sweating of the hands, feet, and face,[2] but this is off-label: the Botox label states that safety and effectiveness for hyperhidrosis in other body areas have not been established.[15] A 2020 systematic review found fewer botulinum toxin studies for the palms than for the underarms.[14] Injections in the palms and soles are also more technically demanding and more uncomfortable than underarm injections, so clinicians often use numbing measures beforehand.

Duration of effect and repeat treatments

Most patients notice less sweating within 7 to 10 days of treatment. The AAD gives typical durations of 3 to 10 months for the underarms or hands, 3 to 6 months for the feet, and about 4 and a half months for the face.[2] In the 52-week underarm trial, the median duration of effect was 197 days and 205 days in the two botulinum toxin dose groups, compared with 96 days with placebo.[6] Repeat injections are required to maintain results.

Pivotal underarm trials: treatment vs placebo or vehicle % responders; each pair is one trial with its own endpoint, so pairs cannot be compared with each other 0% 25% 50% 75% 100% Botulinum toxin A, week 16 Naumann 2001 BMJ; 50% or more sweat reduction 82% Placebo, week 16 Naumann 2001 BMJ 21% Botulinum toxin A, 2-point HDSS gain Lowe 2007 JAAD (52-week trial) 75% Placebo, 2-point HDSS gain Lowe 2007 JAAD 25% Qbrexza, week 4 ATMOS-1/2 pooled; 4-point diary gain 59.5% Vehicle, week 4 ATMOS-1/2 pooled 27.6% % patients meeting each trial's responder definition
Responder rates in three pivotal underarm trials, each against its own placebo or vehicle.[5][6][4] Endpoints and time points differ, and a 2020 systematic review concluded that the current evidence does not allow comparative-effectiveness statements across hyperhidrosis treatments.[14]
Botox is not just cosmetic

Botox has an FDA-approved medical indication for severe axillary hyperhidrosis that is inadequately managed with topical agents in adults.[15] For patients whose insurance assumes a cosmetic use, documenting HDSS severity and prior topical treatment failure can support a coverage request.

Permanent Options: miraDry and Endoscopic Thoracic Sympathectomy

miraDry (microwave thermolysis)

MiraDry is a microwave device, FDA-cleared for primary axillary hyperhidrosis, that focuses heat at the skin-subcutaneous tissue interface, causing irreversible thermolysis of apocrine and eccrine sweat glands.[14] The AAD notes that it destroys sweat glands in 1 or 2 office visits, gives long-lasting results, is cleared for the underarms, and is expensive and not covered by most health insurance plans. Possible side effects include temporary discomfort, underarm swelling, discoloration, and tenderness, and more serious burns and neuropathy.[2] A 2020 systematic review found case reports of median and ulnar nerve injury after microwave thermolysis, with deficits in one patient that had not resolved at 6 months.[14]

Endoscopic thoracic sympathectomy (ETS): compensatory sweating risk

Endoscopic thoracic sympathectomy is a surgical procedure that interrupts the sympathetic chain in the chest. It can permanently stop excessive sweating in the treated area (palms, underarms).[2] It is the treatment of last resort, used when conservative treatments are unsuccessful or intolerable and after accepting secondary compensatory sweating as a potential complication,[10] and the Canadian algorithm reserves it for the palms and soles after failure of all other treatment options.[3] Most patients have some degree of compensatory sweating, ranging from mild to heavy; it develops with time and usually occurs on the belly, legs, or back.[2] Thorough preoperative counseling about this trade-off is essential, and ETS should follow, not precede, adequate trials of topical, iontophoresis, and botulinum toxin therapy.

The sympathetic chain can be interrupted by excision, ablation, or clipping,[9] and the technique and level are details worth discussing with the operating surgeon in advance. Other possible side effects listed by the AAD include excessive dryness in the treated area and a return of excessive sweating.[2] This is part of why this option sits at the far end of the treatment ladder rather than earlier in it.

How long does each treatment last? Duration of clinical effect per treatment cycle. Longer bars = fewer maintenance sessions. 0 wk 10 wk 20 wk Permanent → Aluminum chloride 20% topical Nightly, then once or twice weekly Qbrexza (glycopyrronium) Daily use required Oral oxybutynin Daily use required Iontophoresis (tap water) Maintenance weekly or every other week Botulinum toxin A Median 197 to 205 days (underarm trial) miraDry (microwave) Long-lasting (1 or 2 office visits) Endoscopic thoracic sympathectomy Permanent Approximate duration of effect per treatment cycle
Duration of effect across hyperhidrosis treatments. Topicals and oral medicines require ongoing use; in a 52-week underarm trial, botulinum toxin lasted a median of 197 to 205 days;[6] microwave thermolysis gives long-lasting results and sympathectomy can permanently stop sweating in the treated area.[2]

Ruling Out Secondary Causes: When to Order a Workup

The distinction between primary and secondary hyperhidrosis directly changes management, so it is worth revisiting in more diagnostic detail before discussing cost and access.

FeaturePrimarySecondary
Distribution Focal, bilateral (axillae, palms, soles, face) Generalized or asymmetric
Age of onset Before 25 (often adolescence) Any age, often adult
Family history Often present (genetic basis) Not a typical feature
Sleep Stops during sleep Continues during sleep
Underlying cause Autonomic dysregulation, no identifiable cause Endocrine, neurologic, infectious, malignant, drug
Workup required Usually none Yes: TSH, HbA1c, chest X-ray, drug review

When the history and exam are consistent with secondary disease, generalized distribution, sleep involvement, adult onset without family history, or associated systemic symptoms (fever, weight loss, palpitations, night sweats), a basic laboratory and imaging workup (TSH, fasting glucose or HbA1c, complete blood count, chest X-ray) plus a careful review of prescription and over-the-counter medications is reasonable before initiating symptomatic hyperhidrosis therapy. Identifying and treating the underlying cause, rather than only masking the sweating symptom, is the goal in secondary disease.

Despite how common and treatable hyperhidrosis is, nearly half of affected people never bring it up to a clinician. A 2016 nationally representative survey estimated that 4.8 percent of the U.S. population, about 15.3 million people, has hyperhidrosis, yet only 51 percent had discussed it with a healthcare professional, most often because they did not think it was a medical condition or believed nothing could be done. The authors estimate that only 27 percent of those affected will ultimately be diagnosed.[1] That gap reflects both under-recognition by clinicians, who may not screen for it during routine visits, and under-reporting by patients. Simply asking a direct question about sweating during a visit for another reason often surfaces cases that would otherwise go untreated for years.

The hyperhidrosis treatment gap Only about half of affected people discuss it with a clinician, and about 27% are ultimately diagnosed. 0M 4M 8M 12M 16M People living with hyperhidrosis 4.8% of the US population 15.3M Discuss with a clinician Just over half of affected 51% Receive a formal diagnosis Authors' estimate 27% Millions of people in the US (bar lengths scaled to 15.3M) Source: Doolittle et al., Arch Dermatol Res 2016
The hyperhidrosis care gap in the United States. About 15.3 million people live with hyperhidrosis, but only 51% have discussed it with a healthcare professional, and the survey authors estimate that only 27% will ultimately be diagnosed.[1]

Treatment Cost, Route, and Access in 2026

Cost and access are practical, decision-shaping factors that are easy to overlook in a strictly clinical discussion. The table below summarizes route and access requirements across the treatment ladder. Prices vary widely by pharmacy, clinic, and insurance plan and change often, so they are not listed here; one cost fact the AAD does note is that microwave thermolysis is expensive and not covered by most health insurance plans.[2]

TreatmentRouteAvailabilityPrescription needed?
Aluminum chloride 20% (Drysol) Topical OTC or Rx Both (Rx recommended for 20%)
Qbrexza (glycopyrronium 2.4% cloth) Topical, once daily Rx Yes
Sofdra (sofpironium 12.45% gel) Topical, once daily Rx Yes
Oral oxybutynin (generic) Oral (off-label; trial dose reached 5 mg twice daily) Rx Yes
Oral glycopyrrolate (generic) Oral (off-label) Rx Yes
Iontophoresis Device-based; daily or every 2 to 5 days at first Home or clinic device Ask your clinician
Botulinum toxin A (axillary) In-office injection Clinic Yes (in-office)
miraDry In-office microwave treatment Specialist No (procedure)
Endoscopic thoracic sympathectomy Surgery Thoracic surgery Yes (surgical referral)

What Doesn't Work: Botanicals, "Detox," and Sweat Duct Occlusion Devices

No over-the-counter herbal supplement or "detox" product has rigorous clinical trial evidence supporting efficacy for hyperhidrosis. This is a common target for products making unsupported claims, given how much distress excessive sweating causes and how many patients search for a non-prescription fix.

Products to be skeptical of

"Detox" foot pads, sage or wheatgrass supplements marketed for sweating, and low-level laser sweat-reduction devices sold directly to consumers lack controlled trial evidence. None have been shown in randomized trials to meaningfully reduce sweat production compared with placebo.

A brief evidence summary of commonly marketed non-prescription approaches:

  • Herbal antiperspirant sprays (sage, witch hazel): mild astringent effect at best; no controlled trial evidence of meaningful HDSS improvement
  • Oral "detox" supplements: no plausible mechanism and no trial evidence; sweating is not primarily a toxin-elimination pathway in a way that supplementation would meaningfully alter
  • At-home microneedling or "sweat duct sealing" devices: not FDA-cleared for hyperhidrosis and lack peer-reviewed efficacy data
  • Baking soda or cornstarch powders: can absorb surface moisture and reduce odor but do not reduce underlying gland secretion
  • Extra-strength over-the-counter antiperspirants (aluminum chlorohydrate, non-prescription strength): non-prescription antiperspirants are only effective for mild hyperhidrosis,[2] which is why prescription-strength aluminum chloride is the recommended first-line therapy for most cases[1]

The takeaway: effective hyperhidrosis treatment is well-established, starts with topical aluminum chloride, and much of the early care is accessible via telehealth. Patients frustrated with over-the-counter options are better served moving up the evidence-based ladder than trying unproven alternative products.

Red Flags: When to Seek Prompt Medical Attention

Most hyperhidrosis is a chronic, benign, quality-of-life condition. However, certain features should prompt more urgent evaluation rather than routine hyperhidrosis management:

  • Sudden onset of generalized sweating in adulthood without a clear trigger, particularly with weight loss, fever, or night sweats, which can suggest malignancy, infection, or endocrine disease
  • Sweating accompanied by palpitations, tremor, weight loss, and heat intolerance, suggestive of hyperthyroidism
  • Episodic sweating with headache, palpitations, and hypertension, which can suggest pheochromocytoma and warrants prompt endocrine evaluation
  • Sweating with fever, unexplained weight loss, or lymphadenopathy, which raises concern for lymphoma or another malignancy and should not be attributed to primary hyperhidrosis without further workup
  • New asymmetric sweating (one side of the body only), which can indicate a neurologic lesion and warrants neurologic evaluation
  • Sweating with chest pain, shortness of breath, or diaphoresis at rest, which requires urgent evaluation for acute cardiac or other emergent causes rather than hyperhidrosis management

None of these red flags are typical of primary focal hyperhidrosis, which by definition lacks an identifiable underlying cause and has a longstanding, stable, sleep-sparing pattern. Any deviation from that pattern deserves a second look before defaulting to a hyperhidrosis diagnosis.

Frequently Asked Questions

Everyone sweats in response to heat, exercise, or stress. Hyperhidrosis is sweat production exceeding thermoregulatory needs, and it is diagnosed when the excess sweating creates significant emotional, physical, or social discomfort and harms quality of life.[12] Focal sweating (underarms, palms, soles, or face) that is symmetrical, started before age 25, and stops during sleep is the classic pattern of primary focal hyperhidrosis.[9]

Primary hyperhidrosis is focal (specific body regions), symmetrical, has no identifiable underlying cause, typically starts before age 25, often runs in families, and stops during sleep.[9] Secondary hyperhidrosis usually causes heavy sweating over most of the body, can cause sweating during sleep, and is caused by a medication or an underlying condition such as an endocrine disorder, diabetes, menopause, or a tumor.[9][17][18] Ruling out secondary causes is the first step whenever the presentation is atypical for primary disease.

Non-prescription antiperspirants are only effective for mild hyperhidrosis.[2] Prescription-strength aluminum chloride is the recommended first-line treatment for most cases.[1] It is applied to dry skin at bedtime and allowed to dry completely, nightly until the sweating is under control (usually within a few weeks), then usually once or twice a week.[2] Applying it correctly, to dry skin, at night, matters as much as the concentration itself.

Yes. Qbrexza is a once-daily cloth pre-moistened with 2.4% glycopyrronium solution, an anticholinergic that competitively blocks the acetylcholine receptors on sweat glands.[7] In the pivotal ATMOS-1 and ATMOS-2 phase 3 trials (697 subjects), significantly more Qbrexza patients than vehicle patients achieved a 4-point or greater improvement in sweat severity at week 4 (59.5% vs 27.6% pooled), with a significant reduction in gravimetrically measured sweat production.[4][7] It is FDA-approved for primary axillary hyperhidrosis in patients 9 years of age and older.[7]

In a 52-week underarm trial, the median duration of effect was 197 to 205 days, roughly 6.5 months.[6] The AAD gives typical durations of 3 to 10 months for the underarms or hands, 3 to 6 months for the feet, and about 4 and a half months for the face, and notes that most patients see less sweating within 7 to 10 days.[2] Repeat injections are required to maintain results.

Oral oxybutynin is used off-label for hyperhidrosis. In a randomized placebo-controlled trial, the dose was raised stepwise to 5 mg twice daily over 6 weeks, and dry mouth was the most frequent side effect.[8] A 2017 review called recent longer follow-up studies encouraging but said studies with longer follow-up are needed to establish long-term safety and results.[9] The label warns about heat prostration from decreased sweating and anticholinergic effects such as drowsiness and blurred vision, and advises cautious dosing in older adults.[16] Starting at the lowest effective dose and periodically reassessing whether continued treatment is still needed is the standard approach, particularly in older adults.

Iontophoresis involves placing the hands or feet in a pan of tap water while a direct electric current goes into the water and enters the surface of the skin. The FDA has cleared iontophoresis machines to treat hyperhidrosis on the hands and feet. Sessions usually last 20 to 30 minutes, daily or once every 2 to 5 days at first; results usually appear after 5 to 10 treatments, and most patients then maintain results by treating once a week or every other week. You can buy a machine to use at home.[2] It is considered the primary remedy for palmar and plantar hyperhidrosis.[10]

The Hyperhidrosis Disease Severity Scale (HDSS) is a four-point, single-item scale that rates sweating by tolerability and interference with daily activities; a score of 3 or 4 (barely tolerable or intolerable, frequently or always interfering) is considered severe.[1] In the Canadian algorithm, a score of 2 starts with topical aluminum chloride, with botulinum toxin A or iontophoresis next if that fails. A score of 3 or 4 makes botulinum toxin A and topical aluminum chloride both first-line, with iontophoresis also first-line for palms and soles.[3]

Both are durable options usually considered after other treatments have not worked well enough. MiraDry is FDA-cleared for primary axillary hyperhidrosis and irreversibly destroys sweat glands with focused microwave heat;[14] it takes 1 or 2 office visits, gives long-lasting results, and is not covered by most health insurance plans.[2] Endoscopic thoracic sympathectomy is surgery and the treatment of last resort, after accepting compensatory sweating as a potential complication.[10] Most patients have some degree of compensatory sweating afterward, ranging from mild to heavy, which should be discussed thoroughly with a surgeon before proceeding.[2]

Yes, for most first-line and second-line therapies. A licensed clinician can evaluate your history for secondary causes and prescribe topical aluminum chloride, Qbrexza, Sofdra, and oral oxybutynin or glycopyrrolate through a synchronous telehealth visit. Procedural treatments, botulinum toxin injections, iontophoresis device fitting, miraDry, and ETS, require in-person visits and typically a dermatology or surgical referral.

Coverage varies by plan and treatment, and prices change often, so check with your insurer or pharmacy before starting. Plans that cover the newer topical anticholinergics, Qbrexza and Sofdra, may ask for documentation of severity (such as an HDSS score) and prior topical treatment. Botox has an FDA-approved medical indication for severe axillary hyperhidrosis inadequately managed with topical agents in adults,[15] which can matter when coverage is reviewed. Microwave thermolysis is not covered by most health insurance plans.[2]

Sudden-onset generalized sweating in adulthood, sweating with unexplained weight loss, fever, or night sweats, sweating with palpitations and heat intolerance, new asymmetric sweating, and sweating accompanied by chest pain or shortness of breath are not typical of primary hyperhidrosis and warrant prompt medical evaluation rather than routine hyperhidrosis management. Primary hyperhidrosis has a stable, longstanding, sleep-sparing pattern; any significant deviation from that pattern deserves further workup.

How to cite this guide

Bhavsar P. Hyperhidrosis. TeleDirectMD Health Guides. Last reviewed July 18, 2026. https://teledirectmd.com/health-guides/hyperhidrosis-guide/

References

  1. Doolittle J, Walker P, Mills T, Thurston J. Hyperhidrosis: an update on prevalence and severity in the United States. Arch Dermatol Res. 2016;308(10):743-749. Full text
  2. American Academy of Dermatology Association. Hyperhidrosis: Diagnosis and treatment. Last updated July 16, 2024. Accessed November 15, 2026. Full text
  3. Solish N, Bertucci V, Dansereau A, et al. A comprehensive approach to the recognition, diagnosis, and severity-based treatment of focal hyperhidrosis: recommendations of the Canadian Hyperhidrosis Advisory Committee. Dermatol Surg. 2007;33(8):908-923. Full text
  4. Glaser DA, Hebert AA, Nast A, et al. Topical glycopyrronium tosylate for the treatment of primary axillary hyperhidrosis: Results from the ATMOS-1 and ATMOS-2 phase 3 randomized controlled trials. J Am Acad Dermatol. 2019;80(1):128-138.e2. Full text
  5. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323(7313):596-599. Full text
  6. Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol. 2007;56(4):604-611. Full text
  7. QBREXZA (glycopyrronium) cloth, for topical use. Prescribing information. DailyMed, U.S. National Library of Medicine. Label revised 11/2022; DailyMed page updated May 21, 2026. Accessed November 15, 2026. Full text
  8. Wolosker N, de Campos JR, Kauffman P, Puech-Leão P. A randomized placebo-controlled trial of oxybutynin for the initial treatment of palmar and axillary hyperhidrosis. J Vasc Surg. 2012;55(6):1696-1700. Full text
  9. Delort S, Marchi E, Corrêa MA. Oxybutynin as an alternative treatment for hyperhidrosis. An Bras Dermatol. 2017;92(2):217-220. (Narrative review.) Full text
  10. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Therapeutic options. J Am Acad Dermatol. 2019;81(3):669-680. Full text
  11. Bushara KO, Park DM, Jones JC, Schutta HS. Botulinum toxin--a possible new treatment for axillary hyperhidrosis. Clin Exp Dermatol. 1996;21(4):276-278. Full text
  12. Nawrocki S, Cha J. The etiology, diagnosis, and management of hyperhidrosis: A comprehensive review: Etiology and clinical work-up. J Am Acad Dermatol. 2019;81(3):657-666. Full text
  13. SOFDRA (sofpironium) gel, for topical use. Prescribing information. DailyMed, U.S. National Library of Medicine. DailyMed page updated September 22, 2025. Accessed November 15, 2026. Full text
  14. Stuart ME, Strite SA, Gillard KK. A systematic evidence-based review of treatments for primary hyperhidrosis. J Drug Assess. 2020;10(1):35-50. Full text
  15. BOTOX (onabotulinumtoxinA) for injection. Prescribing information. DailyMed, U.S. National Library of Medicine. DailyMed page updated February 2, 2026. Accessed November 15, 2026. Full text
  16. Oxybutynin chloride tablets. Prescribing information (Major Pharmaceuticals). DailyMed, U.S. National Library of Medicine. DailyMed page updated September 19, 2025. Accessed November 15, 2026. Full text
  17. American Academy of Dermatology Association. Hyperhidrosis: Causes. Last updated July 16, 2024. Accessed November 15, 2026. Full text
  18. American Academy of Dermatology Association. Hyperhidrosis: Signs and symptoms. Last updated July 16, 2024. Accessed November 15, 2026. Full text

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician, founder of TeleDirectMD, and the physician editor of the TeleDirectMD Health Guides. He practices multi-state urgent care telemedicine with hospitalist experience.

Medically reviewed by Parth Bhavsar, MD. Last reviewed and fully rewritten July 18, 2026.